The exploration provides a detailed explanation of how a multimodal HL tissue editing therapy targets r/r HL cells and the adjacent microenvironment, highlighting mTOR as a critical therapeutic bottleneck due to concerted transcription modulation and MEPED as a regulator of HL stress responses and HL hallmarks. This evidence concerns the gene MTOR and Hodgkins lymphoma.